JOHN GERECITANO, M.D., PH.D.
GLOBAL MEDICAL HEAD
LYMPHOMA/LEUKEMIA DISEASE AREA LEADER
ONCOLOGY RESEARCH & DEVELOPMENT
JOHNSON & JOHNSON INNOVATIVE MEDICINE
John Gerecitano, M.D., Ph.D. is the Global Medical Head of the Lymphoma/Leukemia Disease Area at Johnson & Johnson Innovative Medicine.
In this role, John is responsible for leading the lymphoma and leukemia scientific strategies, which span oversight of a robust portfolio of assets in early development and translational sciences.
Prior to this role, John served as Clinical Lead and Global Head of Early Development for lymphoma programs. Since 2018, he has also served as the chair of the Lymphoma Disease Strategy Team – a forerunner of the newly created Lymphoma/Leukemia Disease Area.
John graduated from the College of Human Ecology at Cornell University in 1991 and went on to attend New York University’s Medical Scientist Training Program after a 10-month Research Internship with the R&D group of a global pharmaceutical company.
He completed his internship and residency in Internal Medicine at the University of Pennsylvania in 2003, and his fellowship in Hematology and Medical Oncology at Memorial Sloan-Kettering Cancer Center (MSKCC) in 2006.
From 2006 to 2018, John was a practicing oncologist on the lymphoma faculty and became the Clinical Director of Lymphoma Care at Memorial Sloan-Kettering Cancer Center.
John was also a founding member of the Phase 1 Clinical Trials Program for Solid Tumors and Lymphoma at MSKCC. During his 11 years on the faculty of MSKCC and Weil Cornell Medical College, John was the principal investigator (PI) of over 20 Phase 1 trials, the global PI of the Phase 3 CHRONOS 3 trial and served as a key opinion leader in the fields of lymphoma and Phase 1 development on the advisory boards of several pharmaceutical companies.